이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

모든 환자의 집에서 유지약 복용을 돕기 위한 다양한 프로그램에 대한 연구

2026년 10월 2일 업데이트: Children's Oncology Group

ALL이 있는 아동, 청소년 및 청년의 위험 기반 6MP 준수 강화 전략 - 파일럿 연구

This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a special cap called TrackCap™ that electronically records when the medication bottle is opened. Researchers are trying a new program to help patients be better at taking their 6MP like they're supposed to. This new program may help patients to remember to take their 6MP medication.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. Collect data on the feasibility of a phase 3 adherence-enhancing 2 parallel 2-arm randomized clinical trial.

Ia. Estimate participation rates, refusal reasons, and attrition rates. Ib. Evaluate rates of completeness of all aspects of the study (surveys [rates of missing elements]; MEMS® TrackCap™ return rates; maintenance form return rates from site clinical research assistants [CRAs]; blood samples for pharmacogenetics and deoxyribonucleic acid [DNA]-incorporated thioguanine nucleotide [DNA-TG] levels).

SECONDARY OBJECTIVES:

I. Among baseline non-adherers, estimate the impact of ultra-intensified intervention package (U-iIP) versus (vs.) intervention package (IP) on 6MP adherence.

II. Among baseline adherers, estimate the impact of patient-empowered intervention package (pIP) vs. education alone (EDU) on 6MP adherence.

OUTLINE:

Patients receive the Patient Supply Kit containing an empty MEMS® medication bottle with TrackCap™ with child resistant medication bottles and child resistant standard caps, and written instructions for the patient and pharmacist, along with their 6MP prescription. Beginning on day 1 cycle 1 of Maintenance Therapy, patients start using the MEMS® medication bottle with TrackCap™. Clinical research assistants contact patients and parents by telephone the next day to confirm that TrackCap™ is being used, to identify any obstacles, and to determine solutions. Patients are instructed to return the first MEMS® TrackCap™ to the clinic on day 1 of Maintenance cycle 2. Patients are then assigned to 1 of 2 groups based on baseline adherence rates (adherers [adherence rate >= 95%] and non-adherers [adherence rate < 95%]).

NON-ADHERERS: Patients are randomized to 1 of 2 arms during cycle 2 of Maintenance therapy.

ARM I (IP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the multimedia interactive patient/parent/other adult education (MIPE) program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. A designated parent/other adult is selected and trained briefly in prompting and supervising the patient to take 6MP daily by the CRA on day 1 of Maintenance cycle 3. Patients also receive customized printed medication schedules approximately every 4 weeks (days 1, 29, and 57) during Maintenance cycles 3-5 (during scheduled clinic visits) from their healthcare provider. Patients and/or the parent/other adult receive automated customized electronic reminders delivered via smartphone according to the patient's electronic 6MP schedule. Once the designated parent/other adult receives the customized electronic reminder for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Patients and designated parents/other adults will be instructed to electronically indicate when 6MP has been taken (indicative of directly supervised therapy [DST] execution). Additionally, patients undergo blood sample collection on the study.

ARM II (U-iIP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. A designated parent/other adult is selected and trained briefly in prompting and supervising the patient to take 6MP daily by the CRA on day 1 of Maintenance cycle 3. Patients also receive customized printed medication schedules approximately every 4 weeks (days 1, 29, and 57) during Maintenance cycles 3-5 (during scheduled clinic visits) from their healthcare provider. Patients and/or the parent/other adult receive automated customized electronic reminders delivered via smartphone according to the patient's electronic 6MP schedule. Once the designated parent/other adult receives the reminder for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Patients and designated parents/other adults will be instructed to electronically indicate when 6MP has been taken (indicative of DST execution). If there is no response by the designated parent/other adult indicating 6MP ingestion within 1 hour of the scheduled time, additional automated reminders are sent. The Adherence Study Coordinating Center will evaluate electronic responses (indicative of DST execution) every 4 weeks. The DST response rates will be communicated to the COG sites, identifying the patients as low DST responders (response rate: < 85%) or high DST responders (response rate: ≥ 85%), along with instructions to serve as a guideline for communicating these results when reviewing them with their patient. DST response rates will be reviewed with the patient every 4 weeks at the clinic visit by the healthcare provider for all U-iIP patients (irrespective of response rate). Patients (and their designated caregiver) receive booster MIPE videos to view on their smartphone every 4 weeks (Days 1, 29, and 57) during Maintenance cycles 3-5, with content that reinforces the importance of 6MP in treating leukemia, having a daily routine for 6MP ingestion, and executing/confirming directly supervised therapy (DST) with each dose, and review common barriers to 6MP ingestion and DST execution (e.g., patient away from home, change in daily schedule), address additional barriers significantly associated with DST execution, and feature examples of patients/other adults self-identifying barriers (e.g., parent not always home at time of 6MP, lack of organizational skills, etc.), and provide specific steps to overcome the barriers. Additionally, patients undergo blood sample collection on the study.

ADHERERS: Patients are randomized to 1 of 2 arms during cycle 2 of Maintenance therapy.

ARM III (EDU: Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. Additionally, patients undergo blood sample collection on the study.

ARM IV (pIP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. On day 1 of Maintenance cycle 3, patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic. On day 1 of Maintenance cycle 3, the patient and a designated parent/other adult are trained to set daily reminders on their smartphones at the time the 6MP is due, and to use the "snooze" function to allow repeated reminders in case the medication cannot be taken when the alarm first goes off. The designated parent/other adult is also trained briefly by the CRA in prompting and supervising the patient to take 6MP daily. Once the designated parent/other adult hears the smartphone alarm for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Additionally, patients undergo blood sample collection on the study.

연구 유형

중재적

등록 (추정된)

64

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • Children's Hospital of Alabama
    • Arkansas
      • Little Rock, Arkansas, 미국, 72202-3591
        • Arkansas Children's Hospital
    • California
      • Oakland, California, 미국, 94611
        • Kaiser Permanente-Oakland
    • Delaware
      • Wilmington, Delaware, 미국, 19803
        • Alfred I duPont Hospital for Children
    • Florida
      • Fort Myers, Florida, 미국, 33908
        • Golisano Children's Hospital of Southwest Florida
      • Jacksonville, Florida, 미국, 32207
        • Nemours Children's Clinic-Jacksonville
      • Orlando, Florida, 미국, 32827
        • Nemours Children's Hospital
      • Orlando, Florida, 미국, 32803
        • AdventHealth Orlando
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Riley Hospital for Children
    • Maine
      • Bangor, Maine, 미국, 04401
        • Eastern Maine Medical Center
    • Maryland
      • Baltimore, Maryland, 미국, 21215
        • Sinai Hospital of Baltimore
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • C S Mott Children's Hospital
    • Nevada
      • Las Vegas, Nevada, 미국, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, 미국, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, 미국, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, 미국, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, 미국, 89502
        • Renown Regional Medical Center
    • New York
      • Buffalo, New York, 미국, 14263
        • Roswell Park Cancer Institute
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Children's Hospital of Philadelphia
    • Rhode Island
      • Providence, Rhode Island, 미국, 02903
        • Rhode Island Hospital
    • South Carolina
      • Columbia, South Carolina, 미국, 29203
        • Prisma Health Richland Hospital
    • Texas
      • Austin, Texas, 미국, 78723
        • Dell Children's Medical Center of Central Texas
      • San Antonio, Texas, 미국, 78229
        • Methodist Children's Hospital of South Texas
    • Virginia
      • Falls Church, Virginia, 미국, 22042
        • Inova Fairfax Hospital
      • Norfolk, Virginia, 미국, 23507
        • Children's Hospital of The King's Daughters
    • Washington
      • Tacoma, Washington, 미국, 98431
        • Madigan Army Medical Center
    • Wisconsin
      • Green Bay, Wisconsin, 미국, 54301
        • Saint Vincent Hospital Cancer Center Green Bay

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

10년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age: >= 10 years and =< 25 years
  • Previously enrolled onto AALL1732
  • Consented to the AALL1732 mercaptopurine adherence correlative study
  • Maintenance therapy has not yet begun
  • English or Spanish-speaking (patient and parent/other adult)
  • Planning to receive 6MP (as tablets) during maintenance phase of therapy
  • Able and willing to use the MEMS® TrackCap™ (e.g., not using a pillbox or prescribed liquid 6MP)
  • Has a designated parent/other adult who is willing to enter into a mutual agreement with the patient to participate in a daily supervised medication administration routine
  • Patient/parent/other adult must be willing to use a smartphone to receive medication reminders
  • Receiving treatment at a Children's Oncology Group (COG) institution in the United States

Exclusion Criteria:

  • Patients who have previously participated in or are currently participating in another intervention clinical trial designed to improve adherence

  • Regulatory requirements

    • All patients and/or their parents or legal guardians must sign a written informed consent
    • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Adherers arm III (EDU)

Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. Additionally, patients undergo blood sample collection on the study.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Receive Patient Supply Kit

View MIPE program videos

Review booster MIPE videos

Use MEMS® with TrackCap™

Undergo training for prompting and supervising 6MP

실험적: Adherers arm IV (pIP)

See Detailed Description.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Given PO

다른 이름들:
  • 6MP
  • 퓨리네톨
  • 3H-퓨린-6-티올
  • 6 티오히폭산틴
  • 6 티오퓨린
  • 6-메르캅토퓨린
  • 6-메르캅토퓨린 일수화물
  • 6-푸리네티올
  • 6-티오퓨린
  • 6-티옥소퓨린
  • 6H-퓨린-6-티온, 1,7-디하이드로-(9CI)
  • 7-메르캅토-1,3,4,6-테트라자인덴
  • 알티-메르캅토퓨린
  • 아자티오퓨린
  • Bw 57-323H
  • 플로코필
  • 이스미푸르
  • 류케린
  • 류푸린
  • 메르카루킴
  • 머칼루킨
  • 메르캅티나
  • 메르캅토푸리눔
  • 메르카푸린
  • 머른
  • NCI-C04886
  • 푸리-네트톨
  • 퓨리메톨
  • 퓨린, 6-메르캅토-
  • 퓨린-6-티올(8CI)
  • 퓨린-6-티올, 일수화물
  • 퓨리네티올
  • U-4748
  • WR-2785

Receive Patient Supply Kit

View MIPE program videos

Review booster MIPE videos

Use MEMS® with TrackCap™

Undergo training for prompting and supervising 6MP

Receive DST

Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits

Receive automated customized electronic reminders via smartphone

Receive additional automated reminders

Manually activate daily smartphone reminders with successive alerts (using the "snooze" function)

Receive electronic reminders with successive alerts (using the "snooze" function)

실험적: Non-adherers arm I (IP)

See Detailed Description.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Given PO

다른 이름들:
  • 6MP
  • 퓨리네톨
  • 3H-퓨린-6-티올
  • 6 티오히폭산틴
  • 6 티오퓨린
  • 6-메르캅토퓨린
  • 6-메르캅토퓨린 일수화물
  • 6-푸리네티올
  • 6-티오퓨린
  • 6-티옥소퓨린
  • 6H-퓨린-6-티온, 1,7-디하이드로-(9CI)
  • 7-메르캅토-1,3,4,6-테트라자인덴
  • 알티-메르캅토퓨린
  • 아자티오퓨린
  • Bw 57-323H
  • 플로코필
  • 이스미푸르
  • 류케린
  • 류푸린
  • 메르카루킴
  • 머칼루킨
  • 메르캅티나
  • 메르캅토푸리눔
  • 메르카푸린
  • 머른
  • NCI-C04886
  • 푸리-네트톨
  • 퓨리메톨
  • 퓨린, 6-메르캅토-
  • 퓨린-6-티올(8CI)
  • 퓨린-6-티올, 일수화물
  • 퓨리네티올
  • U-4748
  • WR-2785

Receive Patient Supply Kit

View MIPE program videos

Review booster MIPE videos

Use MEMS® with TrackCap™

Undergo training for prompting and supervising 6MP

Receive DST

Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits

Receive automated customized electronic reminders via smartphone

Receive additional automated reminders

Manually activate daily smartphone reminders with successive alerts (using the "snooze" function)

Receive electronic reminders with successive alerts (using the "snooze" function)

Receive customized printed medication schedules

실험적: Non-adherers arm II (U-iIP)

See Detailed Description.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Given PO

다른 이름들:
  • 6MP
  • 퓨리네톨
  • 3H-퓨린-6-티올
  • 6 티오히폭산틴
  • 6 티오퓨린
  • 6-메르캅토퓨린
  • 6-메르캅토퓨린 일수화물
  • 6-푸리네티올
  • 6-티오퓨린
  • 6-티옥소퓨린
  • 6H-퓨린-6-티온, 1,7-디하이드로-(9CI)
  • 7-메르캅토-1,3,4,6-테트라자인덴
  • 알티-메르캅토퓨린
  • 아자티오퓨린
  • Bw 57-323H
  • 플로코필
  • 이스미푸르
  • 류케린
  • 류푸린
  • 메르카루킴
  • 머칼루킨
  • 메르캅티나
  • 메르캅토푸리눔
  • 메르카푸린
  • 머른
  • NCI-C04886
  • 푸리-네트톨
  • 퓨리메톨
  • 퓨린, 6-메르캅토-
  • 퓨린-6-티올(8CI)
  • 퓨린-6-티올, 일수화물
  • 퓨리네티올
  • U-4748
  • WR-2785

Receive Patient Supply Kit

View MIPE program videos

Review booster MIPE videos

Use MEMS® with TrackCap™

Undergo training for prompting and supervising 6MP

Receive DST

Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits

Receive automated customized electronic reminders via smartphone

Receive additional automated reminders

Manually activate daily smartphone reminders with successive alerts (using the "snooze" function)

Receive electronic reminders with successive alerts (using the "snooze" function)

Receive customized printed medication schedules

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Participation
기간: At baseline (by day 1 of maintenance chemotherapy)

Will calculate and report the proportion of patients eligible for the study who participate and will report a corresponding 95% confidence interval.

At baseline (by day 1 of maintenance chemotherapy)
Refusal reasons
기간: At baseline (by day 1 of maintenance chemotherapy)

A single question in a study case report form prompts refusal reason. For each available reason, will calculate and report the proportion of patients reporting that refusal reason as well as corresponding 95% confidence intervals.

At baseline (by day 1 of maintenance chemotherapy)
Attrition
기간: By 60 weeks from day 1 of maintenance chemotherapy

Will calculate and report the proportion of patients who drop out of the study prior to completion among those eligible and enrolled and will report the corresponding 95% confidence interval.

By 60 weeks from day 1 of maintenance chemotherapy
Completion of study measures
기간: By 60 weeks from day 1 of maintenance chemotherapy

Will calculate and report the proportion of patients who complete the following measures by the end of the study follow-up period: study survey submission, MEMS® TrackCap™ return, maintenance form return, and blood sample submission. Will also report the corresponding 95% confidence intervals.

By 60 weeks from day 1 of maintenance chemotherapy

2차 결과 측정

결과 측정
측정값 설명
기간
6-mercaptopurine (6MP) adherence (baseline non-adherers)
기간: By 60 weeks from day 1 of maintenance chemotherapy

Among baseline non-adherers, the proportion of days with protocol defined appropriate medication use during the study follow up period will be captured for each patient using the MEMS cap. Will calculate and report the mean proportion of adherence days by arm and the corresponding 95% confidence interval.

By 60 weeks from day 1 of maintenance chemotherapy
6MP adherence (baseline adherers)
기간: By 60 weeks from day 1 of maintenance chemotherapy

Among baseline adherers, protocol defined appropriate medication use during the study follow up period will be captured for each patient using the MEMS cap. Will calculate and report the proportion with >= 95% adherence over the study follow up period by arm with a corresponding 95% confidence interval.

By 60 weeks from day 1 of maintenance chemotherapy

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Smita Bhatia, Children's Oncology Group

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 4일

기본 완료 (추정된)

2027년 3월 3일

연구 완료 (추정된)

2027년 3월 3일

연구 등록 날짜

최초 제출

2024년 10월 10일

QC 기준을 충족하는 최초 제출

2024년 10월 10일

처음 게시됨 (실제)

2024년 10월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 2일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다